Home  About us Services Partners  Contacts

 

Abreviated CV

Dr Krister Kristianson

 

MSc Pharm, PhD Pharmacology & Toxicology

Assitant Lecturer in Pharmacology Uppsala University 

Assistant Medical Director, Merck Sharp & Dohme, Sweden AB

Director Clinical Research Merck Sharp & Dohme, Sweden AB

Regional Director Clinical Research Scandinavia, Merck & Co Inc

Special assignment project CRISP, Merck & Co Inc, Rahway NJ. USA

Senior Research Coordinator, Department of Clinical Pharmacology, Karolinska Institutet at Huddinge Hospital

Lecturer at the Karolinska Institut on research methodology and quality assurance.

CEO e-Source Technology EMR

CEO and President e-Source Technology CDCM AB

CTO EDC Scandinavia AB

 

Publications last 10 years

 

Krister J Kristianson, Henrik Ljunggren, Lars L Gustafsson, Data extraction from a semi structured electronic medical record system for outpatients:  A model to facilitate the access and use of data for quality control and research,  Health Informatics Journal Vol 15 (4):1-15 2009

 

Lars L Gustafsson, Björn Wettermark,Seher Korkmaz, Marie E Persson, Henrik Almkvist, Paul Hjemdahl, Margaretha Julander, Krister Kristianson, Bo Ringertz, Gunilla Thörnwall- Bergendahl, Nils Wilking,  Strukturerat införande av nya läkemedel i Stockholm, Läkartidningen No 41 (Vol 105) 2008

 

Kennedy LM, Dickstein J, Anker SD, James M, Cook TJ, Kristianson and Willenheimer R.Weight-change as a prognostic marker in 12 550 patients following acute myocardial infarction or with stable coronary artery disease. Eur Heart J. 2006 Dec;27(23):2755-62. Epub 2006 Aug 4.

 

Kjeldsen SE, Lyle PA, Tershakovec AM, Devereux RB, Oparil S, Dahlof B, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Wedel H.  Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Expert Opin Emerg Drugs. 2005 Nov;10(4):729-45. Review.

 

Fossum E, Moan A, Kjeldsen SE, Devereux RB, Julius S, Snapinn SM, Edelman JM, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS,

 

Omvik P, Oparil S, Wedel H, Dahlof B; LIFE Study Group. The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study. J Am Coll Cardiol. 2005 Sep 6;46(5):770-5.

 

Fyhrquist F, Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Hille DA, Lyle PA, Edelman JM, Snapinn SM, Wedel H; LIFE Study Group.  Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy. Hypertension. 2005 Apr;45(4):580-5.

 

Kjeldsen SE, Lyle PA, Kizer JR, Dahlof B, Devereux   RB, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen  H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Snapinn SM, Harris KE, Wedel H; LIFE Study Group. The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study. J Clin Hypertens (Greenwich). 2005Mar;7(3):152-8.

 

Kjeldsen SE, Lyle PA, Kizer JR, Dahlof B, Devereux RB, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Snapinn SM, Harris KE, Wedel H; LIFE Study Group. The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study. J Clin Hypertens (Greenwich). 2005 Mar;7(3):152-8.

 

 

Kennedy LM, Dickstein K, Anker SD, Kristianson K, Willenheimer R; OPTIMAAL Study Group. The prognostic importance of body mass index after complicated myocardial infarction. J Am Coll Cardiol. 2005 Jan 4;45(1):156-8.

 

 

Kizer JR, Dahlof B, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, Wachtell K, Edelman JM, Snapinn SM, Harris KE, Devereux RB. Stroke reduction  in hypertensive adults  with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study. Hypertension. 2005

Jan;45(1):46-52. Epub 2004 Dec 6.

 

Reims HM, Oparil S, Kjeldsen SE, Devereux RB, Julius S, Brady WE, Fyhrquist F, Ibsen H, Lindholm LH, Omvik P, Wedel H, Beevers G, de Faire U, Kristianson K, Lederballe-Pedersen O, Nieminen MS, Dahlof B; LIFE Study Group. Losartan benefits over atenolol in non- smoking hypertensive patients with left ventricular hypertrophy: the LIFE study. Blood Press.

2004;13(6):376-84.

 

Reims HM, Kjeldsen SE, Brady WE, Dahlof B, Devereux RB, Julius S, Beevers G, De Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. Alcohol consumption and cardiovascular risk in hypertensives with left ventricular hypertrophy: The LIFE study. J Hum Hypertens. 2004 Jun;18(6):381-9

 

Hoieggen A, Alderman MH, Kjeldsen SE, Julius S, Devereux RB, De Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, Chen C, Dahlof B; LIFE Study Group  The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int. 2004 Mar;65(3):1041-9.

 

Wachtell K, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlof B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristianson K, Lederballe-Pedersen O, Nieminen MS, Okin PM, Omvik P, Oparil S, Wedel H, Snapinn SM, Aurup P.  Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med. 2003 Dec 2;139(11):901-6.

 

Devereux RB, Dahlof B, Kjeldsen SE, Julius S, Aurup P, Beevers G, Edelman JM, de Faire U, Fyhrquist F, Helle Berg S, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Snapinn S, Wedel H; LIFE Study Group.  Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial. Ann Intern Med. 2003 Aug 5;139(3):169-77

 

Kristianson K, Fyhrquist F, Devereux RB,

Kjeldsen SE, Lindholm LH, Lyle PA, Nieminen MS, Snapinn SM. An analysis of cholesterol control and statin use in the Losartan Intervention for Endpoint Reduction in Hypertension Study. Clin Ther. 2003 Apr;25(4):1186-99.

 

 

Lindholm LH, Ibsen H, Borch-Johnsen K, Olsen MH, Wachtell K, Dahlof B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristianson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman JM, Snapinn S; For the LIFE study group. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens. 2002 Sep;20(9):1879-86.

 

Kjeldsen SE, Dahlof B, Devereux RB, Julius S, Aurup P, Edelman J, Beevers  G, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Snapinn S, Wedel H; LIFE (Losartan Intervention for Endpoint Reduction) Study Group. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA. 2002 Sep 25;288(12):1491-8.

 

 

Kjeldsen SE, Dahlof B, Devereux RB, Julius S, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H.  Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint. Am J Hypertens. 2000 Aug;13(8):899-906.

 

    

 

 

 

 

 

 

 

e-Source Technology EMR

(Founded 2004)

Copyright© 2013

 e-Source Technology CDCM AB